Marc Ditmarsch
Corporate Officer/Principal en FRAZIER LIFESCIENCES ACQUISITION CORPORATION .
Fortuna: - $ al 30/04/2024
Perfil
Marc Ditmarsch is currently the Vice President-Research & Development at NewAmsterdam Pharma Holding BV and the Chief Development Officer at NewAmsterdam Pharma Co. NV.
Previously, he worked as a Medical Director at AstraZeneca BV from 2014 to 2016.
He holds a doctorate degree from Vrije Universiteit Amsterdam.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 22/03/2023 | 0 ( -.--% ) | - $ | 30/04/2024 |
Cargos activos de Marc Ditmarsch
| Empresas | Cargo | Inicio |
|---|---|---|
| FRAZIER LIFESCIENCES ACQUISITION CORPORATION | Corporate Officer/Principal | 01/08/2022 |
NewAmsterdam Pharma Holding BV
 NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million. | Corporate Officer/Principal | 01/01/2020 |
Antiguos cargos conocidos de Marc Ditmarsch.
| Empresas | Cargo | Fin |
|---|---|---|
| AstraZeneca BV | Director Técnico/Científico/I+D | 01/01/2016 |
Formación de Marc Ditmarsch.
| Vrije Universiteit Amsterdam | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| FRAZIER LIFESCIENCES ACQUISITION CORPORATION | Health Technology |
| Empresas privadas | 2 |
|---|---|
NewAmsterdam Pharma Holding BV
NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million. | Health Technology |
| AstraZeneca BV |
- Bolsa de valores
- Insiders
- Marc Ditmarsch